These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26248372)

  • 1. Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.
    Modongo C; Pasipanodya JG; Zetola NM; Williams SM; Sirugo G; Gumbo T
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6337-43. PubMed ID: 26248372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.
    Modongo C; Pasipanodya JG; Magazi BT; Srivastava S; Zetola NM; Williams SM; Sirugo G; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5928-32. PubMed ID: 27458224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.
    van Altena R; Dijkstra JA; van der Meer ME; Borjas Howard JF; Kosterink JG; van Soolingen D; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis.
    Vasconcelos KA; Frota SMMC; Ruffino-Netto A; Kritski AL
    J Bras Pneumol; 2018 Apr; 44(2):85-92. PubMed ID: 29791559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
    Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
    Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
    Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
    Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
    Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Wrohan I; Redwood L; Ho J; Velen K; Fox GJ
    Int J Tuberc Lung Dis; 2021 Jan; 25(1):23-30. PubMed ID: 33384041
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial.
    Garcia-Prats AJ; Rose PC; Draper HR; Seddon JA; Norman J; McIlleron HM; Hesseling AC; Schaaf HS
    Pediatr Infect Dis J; 2018 Dec; 37(12):1199-1203. PubMed ID: 29561515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis.
    Whitehead TC; Lovering AM; Cropley IM; Wade P; Davidson RN
    Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):794-7. PubMed ID: 9923523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
    Sturdy A; Goodman A; José RJ; Loyse A; O'Donoghue M; Kon OM; Dedicoat MJ; Harrison TS; John L; Lipman M; Cooke GS
    J Antimicrob Chemother; 2011 Aug; 66(8):1815-20. PubMed ID: 21642291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
    Zheng X; Zheng R; Hu Y; Werngren J; Forsman LD; Mansjö M; Xu B; Hoffner S
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4786-92. PubMed ID: 27246779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis.
    Vasconcelos KA; Frota SMMC; Ruffino-Netto A; Kritski AL
    Rev Soc Bras Med Trop; 2017; 50(5):646-651. PubMed ID: 29160511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients.
    Javadi MR; Abtahi B; Gholami K; Safari Moghadam B; Tabarsi P; Salamzadeh J
    Iran J Pharm Res; 2011; 10(4):905-11. PubMed ID: 24250429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.
    Modongo C; Sobota RS; Kesenogile B; Ncube R; Sirugo G; Williams SM; Zetola NM
    BMC Infect Dis; 2014 Oct; 14():542. PubMed ID: 25300708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.
    Dijkstra JA; van Altena R; Akkerman OW; de Lange WC; Proost JH; van der Werf TS; Kosterink JG; Alffenaar JW
    Int J Antimicrob Agents; 2015 Sep; 46(3):332-7. PubMed ID: 26228464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
    de Jager P; van Altena R
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):622-7. PubMed ID: 12102302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
    Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
    Am J Audiol; 2020 Jun; 29(2):199-205. PubMed ID: 32320639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?
    Melchionda V; Wyatt H; Capocci S; Garcia Medina R; Solamalai A; Katiri S; Hopkins S; Cropley I; Lipman M
    Eur Respir J; 2013 Oct; 42(4):1148-50. PubMed ID: 24081766
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
    Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Leufkens HG; Mantel-Teeuwisse AK
    BMC Pharmacol Toxicol; 2015 Dec; 16():36. PubMed ID: 26654443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.